Loading...
Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
Introduction: The efficacy and safety of subcutaneous (sc) pasireotide have been evaluated in a Phase III trial. Here, we report safety and efficacy results from a multinational, expanded-access study of pasireotide sc in patients with Cushing's disease (CD) in a real-world setting (clinicaltri...
Na minha lista:
| Udgivet i: | Front Endocrinol (Lausanne) |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6646464/ https://ncbi.nlm.nih.gov/pubmed/31379734 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2019.00436 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|